Business
Waverley Pharma Announces Successful Tender Award for Pemetrexed with NHS England
Waverley Pharma Announces Successful Tender Award for Pemetrexed with NHS England ...
About this update from Waverley Pharma, Inc.
[{"type":"text","content":"\n \n \n \n Waverley Pharma Announces Successful Tender Award for Pemetrexed with NHS England\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n WINNIPEG, MB\n \n ,\n \n May 27, 2021\n \n /CNW/ - Waverley Pharma Inc. (\"Waverley Pharma\" or the \"Company\") (TSXV: WAVE), a Canadian pharmaceutical company, is pleased to announce that its wholly owned Irish subsidiary, Waverley Pharma Europe Limited (\"WPEL\"), has been awarded exclusive distribution rights for two strengths of pemetrexed (100mg and 500mg) by the National Health Service of\n \n England\n \n (\"NHS England\") for the Central and South West Region of\n \n England\n \n .\n \n \n The awarded NHS England tender is the Company's first awarded tender for pemetrexed in the\n \n United Kingdom\n \n (\"UK\"). The awarded tender has the following projected annual supply quantities based on the award debrief provided by NHS England:\n \n \n \n pemetrexed 100mg – 10,500 vials\n \n \n pemetrexed 500mg – 9,300 vials\n \n \n \n The tender will commence on\n \n June 15, 2021\n \n and has a duration of 12.5 months. WPEL continues to apply for additional tenders in the UK and across the European Union (\"EU\") for pemetrexed and hopes to further increase its presence across\n \n Europe\n \n .\n \n \n \"Waverley Pharma is pleased to announce our first awarded pemetrexed tender in the UK, adding to the continued growth of our oncology presence in this market\" stated\n \n Larry Thiessen\n \n , President and Chief Executive Officer.\n \n \n \n About Waverley Pharma\n \n \n \n Waverley Pharma is a pharmaceutical company focused on the development and commercialization of safe, effective, and affordable cancer therapeutics in the EU,\n \n United Kingdom\n \n and North American markets. The Company, through its subsidiary, is currently selling three generic oncology products in the\n \n United Kingdom\n \n , namely capecitabine, temozolomide and erlotinib. In addition, the Company is developing two generic oncology products in\n \n Europe\n \n , namely pemetrexed and bortezom...